Zevra Therapeutics (FRA:1GDA) COGS-to-Revenue : 0.50 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics COGS-to-Revenue?

Zevra Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was €1.57 Mil. Its Revenue for the three months ended in Mar. 2024 was €3.15 Mil.

Zevra Therapeutics's COGS to Revenue for the three months ended in Mar. 2024 was 0.50.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Zevra Therapeutics's Gross Margin % for the three months ended in Mar. 2024 was 50.27%.

Zevra Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Zevra Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics COGS-to-Revenue Chart

Zevra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.23

0.10

0.07

0.02

0.11

Zevra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.04	0.08	0.05	0.15	0.50

Zevra Therapeutics COGS-to-Revenue Calculation

Zevra Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.701	/	25.182
	=	0.11

Zevra Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.567	/	3.151
	=	0.50

Zevra Therapeutics (FRA:1GDA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Zevra Therapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1.567 / 3.151
	=	50.27 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Zevra Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zevra Therapeutics (FRA:1GDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

ZVRA:USA 1GDA:Germany

Address

1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747

Website

https://www.zevra.com

Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines